Sign up to save your podcasts
Or
Share Episode #111| Bench to Bedside: Bioprinting Innovation Virtual Event Recording
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode #111| Bench to Bedside: Bioprinting Innovation Virtual Event Recording
Everyone talks about printing organs, but the closest thing to real impact often starts with something less flashy and far more practical: the materials. We bring together founders and operators working across bioprinted implants, structural bone substitutes, cryopreserved tissue models, and natural biopolymer manufacturing to answer one question that matters: what actually makes advanced biofabrication translate from bench to bedside?
We dig into bone regeneration and why scaffolds fail when they can’t balance strength, vascular support, and predictable resorption. You’ll hear how absorbable polyurethane platforms aim to avoid acidic degradation while letting teams program mechanics and timelines, plus how 3D printed beta-tricalcium phosphate ceramics can deliver structural consistency and then remodel into native bone. The conversation stays grounded in the realities that decide adoption: predicates and evidence expectations for FDA 510(k), the heavier burden of EU MDR, and the uncomfortable truth that clearance doesn’t guarantee reimbursement.
Then we shift to new approach methodologies for drug development, where cryobioprinting tackles the biggest blocker in bioprinted tissues: logistics. If tissues can be frozen, inventoried, shipped, and used on demand, bioprinting becomes a consumable workflow instead of an artisanal one-off. We close with a candid translation playbook for natural biopolymers and a high-volume pediatric use case: dissolvable chitosan ear tubes designed to reduce repeat surgeries, plus the pricing and coverage strategy needed to make that upgrade viable.
Subscribe, share this with a builder in medtech or biotech, and leave a review with your biggest takeaway: which bottleneck matters most right now, materials, regulation, reimbursement, or scale-up?
Event link: https://3dheals.com/bench-to-bedside-bioprinting-innovations/
YouTube highlights: Stay tuned
Send us Fan Mail
Support the show
Subscribe to our premium version and support the show.
Follow us:
Twitter
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel
About Pitch3D
View all episodes
By 3DHEALS
5
22 ratings
Everyone talks about printing organs, but the closest thing to real impact often starts with something less flashy and far more practical: the materials. We bring together founders and operators working across bioprinted implants, structural bone substitutes, cryopreserved tissue models, and natural biopolymer manufacturing to answer one question that matters: what actually makes advanced biofabrication translate from bench to bedside?
We dig into bone regeneration and why scaffolds fail when they can’t balance strength, vascular support, and predictable resorption. You’ll hear how absorbable polyurethane platforms aim to avoid acidic degradation while letting teams program mechanics and timelines, plus how 3D printed beta-tricalcium phosphate ceramics can deliver structural consistency and then remodel into native bone. The conversation stays grounded in the realities that decide adoption: predicates and evidence expectations for FDA 510(k), the heavier burden of EU MDR, and the uncomfortable truth that clearance doesn’t guarantee reimbursement.
Then we shift to new approach methodologies for drug development, where cryobioprinting tackles the biggest blocker in bioprinted tissues: logistics. If tissues can be frozen, inventoried, shipped, and used on demand, bioprinting becomes a consumable workflow instead of an artisanal one-off. We close with a candid translation playbook for natural biopolymers and a high-volume pediatric use case: dissolvable chitosan ear tubes designed to reduce repeat surgeries, plus the pricing and coverage strategy needed to make that upgrade viable.
Subscribe, share this with a builder in medtech or biotech, and leave a review with your biggest takeaway: which bottleneck matters most right now, materials, regulation, reimbursement, or scale-up?
Event link: https://3dheals.com/bench-to-bedside-bioprinting-innovations/
YouTube highlights: Stay tuned
Send us Fan Mail
Support the show
Subscribe to our premium version and support the show.
Follow us:
Twitter
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel
About Pitch3D